SCHEMBL2223022

SCHEMBL2223022

Sc1cccc(OCc2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.62
BCHE P06276 3/20 0.59
CYP4F2 P78329 1/20 0.59
CYP4A11 Q02928 1/20 0.59
MAOA P21397 1/20 0.57
NR4A2 P43354 1/20 0.57
ALOX5 P09917 1/20 0.56
LCK P06239 1/20 0.54
GRM5 P41594 1/20 0.51
CCNB2 O95067 1/20 0.51
CDK1 P06493 1/20 0.51
CDK4 P11802 1/20 0.51
CCNB1 P14635 1/20 0.51
CCND1 P24385 1/20 0.51
CCNB3 Q8WWL7 1/20 0.51
SMPD1 P17405 1/20 0.51
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
PKM P14618 2/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9278442 0.98 MAOB (0.61) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL9278438 0.98 MAOB (0.61) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL17591456 0.89 F10 (0.54) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL1268719 0.86 MAOB (0.81) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL28182081 0.84 MAOB (0.79) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL9283044 0.84 MAOB (0.47) MAOBBCHECYP4F2CYP4A11MAOA
SCHEMBL22964331 0.84 SMN1; SMN2 (0.51) MAOBBCHECYP4F2CYP4A11MEN1
SCHEMBL22964174 0.84 MAOB (0.66) MAOBMAOANR4A2KDM4EALDH1A1
SCHEMBL22597071 0.82 MAOB (0.67) MAOBMAOANR4A2
SCHEMBL15761340 0.82 BCHE (0.70) MAOBBCHECYP4F2CYP4A11MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012073249-A1 A NOVEL PROCESS FOR THE PREPARATION OF 3-(BENZYLOXY)- BENZENETHIOL, A KEY INTERMEDIATE FOR THE PREPARATION OF PHARMACEUTICAL DRUGS. ARCH PHARMALABS LIMITED (IN) 2012-06-07 WO claimed
US-10961231-B2 NTCP inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-03-30 US disclosed
US-10961231-B2 NTCP inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-03-30 US disclosed
US-20210040072-A1 NTCP Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-02-11 US disclosed
US-20210040072-A1 NTCP Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-02-11 US disclosed
CN-112218878-A NTCP inhibitors 北京生命科学研究所 2021-01-12 CN disclosed
WO-2020215267-A1 USE OF NTCP INHIBITORS IN PREVENTING AND TREATING HEPATOCARCINOGENESIS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-10-29 WO disclosed
US-10081646-B2 Heterobicyclic sphingosine 1-phosphate analogs BIOGEN MA INC. (US) 2018-09-25 US disclosed
US-20180002356-A1 HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN MA INC. 2018-01-04 US disclosed
US-9708353-B2 Heterobicyclic sphingosine 1-phosphate analogs BIOGEN MA INC. (US) 2017-07-18 US disclosed
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs BIOGEN IDEC MA INC. (US) 2010-06-24 US disclosed
WO-2010051030-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2010-05-06 WO disclosed
WO-2010051031-A1 HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2010-05-06 WO disclosed
JP-2010018531-A METHOD FOR PRODUCING 3-BENZYLOXYBENZENETHIOL SUMITOMO SEIKA CHEM CO LTD 2010-01-28 JP disclosed
US-20080207941-A1 Process for Producing 2-Amino-2-[2-[4-(3-Benzyloxyphenylthio)-2-Chlorophenyl]Ethyl]-1,3-Propanediol Hydrochloride and Hydrates Thereof, and Intermediates in the Production Thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
US-20080207941-A1 Process for Producing 2-Amino-2-[2-[4-(3-Benzyloxyphenylthio)-2-Chlorophenyl]Ethyl]-1,3-Propanediol Hydrochloride and Hydrates Thereof, and Intermediates in the Production Thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
WO-2008078563-A1 PROCESS FOR PRODUCTION OF 3-BENZYLOXYBENZENETHIOL SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2008-07-03 WO disclosed
CN-101072752-A Method for producing 2-amino-2- [ 2- [ 4- (3-benzyloxyphenylthio) -2-chlorophenyl ] ethyl ] -1, 3-propanediol hydrochloride or hydrate thereof and intermediate for producing same KYORIN SEIYAKU KK (JP) 2007-11-14 CN disclosed
EP-1806338-A1 PROCESS FOR PRODUCING 2-AMINO-2-[2-[4-(3-BENZYLOXY­PHENYLTHIO)-2-CHLOROPHENYL[ETHYL]-1,3-PROPANEDIOL HYDROCHLORIDE OR HYDRATE THEREOF AND INTERMEDIATE FOR THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
US-20070042968-A1 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease SCHERING CORPORATION 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160258-A1 Bicyclic aryl sphingosine 1-phosphate analogs S1PR1, S1PR3, S1PR4 MAOB 3559/4885BCHE 4511/4885CYP4F2 3251/4885
US-20180002356-A1 HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR2, S1PR4 MAOB 4221/4885BCHE 4600/4885CYP4F2 3768/4885
US-20210040072-A1 NTCP Inhibitors HAVCR2, NPC1, HMGCR MAOB 4651/4885BCHE 862/4885CYP4F2 1389/4885
US-20080207941-A1 Process for Producing 2-Amino-2-[2-[4-(3-Benzyloxyphenylthio)-2-Chlorophenyl]Ethyl]-1,3-Propanediol Hydrochloride and Hydrates Thereof, and Intermediates in the Production Thereof NAT1, ACR, NOD1 MAOB 1458/4885BCHE 4182/4885CYP4F2 69/4885
US-10961231-B2 NTCP inhibitors HAVCR2, NPC1, HMGCR MAOB 4651/4885BCHE 862/4885CYP4F2 1389/4885
US-20070042968-A1 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease PRSS1, PRSS3, HPN MAOB 2289/4885BCHE 1115/4885CYP4F2 3019/4885
US-10081646-B2 Heterobicyclic sphingosine 1-phosphate analogs S1PR1, S1PR2, S1PR4 MAOB 4221/4885BCHE 4600/4885CYP4F2 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.